OA10996A - Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists - Google Patents

Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists Download PDF

Info

Publication number
OA10996A
OA10996A OA9900057A OA9900057A OA10996A OA 10996 A OA10996 A OA 10996A OA 9900057 A OA9900057 A OA 9900057A OA 9900057 A OA9900057 A OA 9900057A OA 10996 A OA10996 A OA 10996A
Authority
OA
OAPI
Prior art keywords
methylamino
phenylethyl
hydroxypyrrolidin
propylbenzamide
hydroxy
Prior art date
Application number
OA9900057A
Other languages
English (en)
Inventor
Fumitaka Ito
Hiroshi Kondo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA10996A publication Critical patent/OA10996A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
OA9900057A 1996-09-18 1999-03-12 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists OA10996A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB96/00957 1996-09-18

Publications (1)

Publication Number Publication Date
OA10996A true OA10996A (en) 2001-11-06

Family

ID=11004480

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900057A OA10996A (en) 1996-09-18 1999-03-12 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists

Country Status (38)

Country Link
US (7) US6201007B1 (es)
EP (1) EP0934264B1 (es)
JP (2) JP3195368B2 (es)
KR (1) KR100339666B1 (es)
CN (1) CN1237962A (es)
AP (1) AP1016A (es)
AR (1) AR008168A1 (es)
AT (1) ATE249433T1 (es)
AU (1) AU719895B2 (es)
BG (1) BG64194B1 (es)
BR (1) BR9711506A (es)
CA (1) CA2266006C (es)
CO (1) CO4920224A1 (es)
DE (1) DE69724805T2 (es)
DK (1) DK0934264T3 (es)
DZ (1) DZ2309A1 (es)
EA (1) EA001341B1 (es)
ES (1) ES2205248T3 (es)
HR (1) HRP970509A2 (es)
ID (1) ID19611A (es)
IL (3) IL147368A0 (es)
IS (1) IS4992A (es)
MA (1) MA26441A1 (es)
NO (1) NO313550B1 (es)
NZ (1) NZ334439A (es)
OA (1) OA10996A (es)
PA (1) PA8437201A1 (es)
PE (1) PE109998A1 (es)
PL (1) PL332546A1 (es)
PT (1) PT934264E (es)
SK (1) SK32799A3 (es)
TN (2) TNSN97092A1 (es)
TR (1) TR199900590T2 (es)
TW (1) TW432047B (es)
UA (1) UA60310C2 (es)
WO (1) WO1998012177A1 (es)
YU (1) YU13899A (es)
ZA (1) ZA978358B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051587A1 (fr) 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
EP0982297A3 (en) * 1998-08-24 2001-08-01 Pfizer Products Inc. Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
AU2002247886A1 (en) * 2001-04-30 2002-11-11 Pfizer Products Inc. Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
CA2477634A1 (en) * 2002-02-28 2003-09-04 Pfizer Products Inc. Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n-{2{n-methyl-n-4-(n-propylamino-carbonyl)phenyl]amino-2-phenyl}-ethylpyrrolidine
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
US7423147B2 (en) * 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
US7746514B2 (en) * 2004-04-14 2010-06-29 Hung-Yi Hsu Scanner and exposure control method thereof
WO2007081978A2 (en) * 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulators of hepatocyte growth factor / c-met activity
CA2653940C (en) 2006-05-30 2015-07-14 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
AU2007265238A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzamide modulators of the histamine H3 receptor
CA2706328C (en) 2007-11-20 2016-04-19 Janssen Pharmaceutica N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
WO1994018165A1 (en) 1993-02-12 1994-08-18 Pfizer Inc. Sulfonamide compounds as opioid k-receptor agonists
IL117440A0 (en) 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process

Also Published As

Publication number Publication date
ES2205248T3 (es) 2004-05-01
US6294569B2 (en) 2001-09-25
CA2266006C (en) 2003-11-04
ZA978358B (en) 1999-03-17
NZ334439A (en) 2000-09-29
EP0934264A1 (en) 1999-08-11
IL147367A0 (en) 2002-08-14
NO313550B1 (no) 2002-10-21
HRP970509A2 (en) 1998-08-31
SK32799A3 (en) 2000-09-12
US6310061B2 (en) 2001-10-30
MA26441A1 (fr) 2004-12-20
WO1998012177A1 (en) 1998-03-26
TNSN97156A1 (fr) 2005-03-15
YU13899A (sh) 2000-03-21
BG103239A (en) 1999-09-30
IL147368A0 (en) 2002-08-14
PL332546A1 (en) 1999-09-13
US20010011091A1 (en) 2001-08-02
BG64194B1 (bg) 2004-04-30
CN1237962A (zh) 1999-12-08
IS4992A (is) 1999-03-05
US6303602B1 (en) 2001-10-16
PE109998A1 (es) 1999-01-13
US6294557B1 (en) 2001-09-25
ID19611A (id) 1998-07-23
AP1016A (en) 2001-10-08
PT934264E (pt) 2004-01-30
US6307061B2 (en) 2001-10-23
TW432047B (en) 2001-05-01
US20010009921A1 (en) 2001-07-26
DK0934264T3 (da) 2004-01-26
EA199900209A1 (ru) 1999-10-28
BR9711506A (pt) 1999-08-24
PA8437201A1 (es) 1999-12-27
JP2000516634A (ja) 2000-12-12
KR20000036225A (ko) 2000-06-26
US6313302B2 (en) 2001-11-06
JP3195368B2 (ja) 2001-08-06
IL128959A0 (en) 2000-02-17
AU719895B2 (en) 2000-05-18
DE69724805T2 (de) 2004-07-01
UA60310C2 (uk) 2003-10-15
NO991294D0 (no) 1999-03-17
CO4920224A1 (es) 2000-05-29
JP2001316344A (ja) 2001-11-13
CA2266006A1 (en) 1998-03-26
AP9701082A0 (en) 1997-10-31
AR008168A1 (es) 1999-12-09
US20010020024A1 (en) 2001-09-06
TNSN97092A1 (ar) 1999-12-31
ATE249433T1 (de) 2003-09-15
US20010014683A1 (en) 2001-08-16
EP0934264B1 (en) 2003-09-10
EA001341B1 (ru) 2001-02-26
US20010008890A1 (en) 2001-07-19
KR100339666B1 (ko) 2002-06-05
US6201007B1 (en) 2001-03-13
DE69724805D1 (de) 2003-10-16
NO991294L (no) 1999-03-17
DZ2309A1 (fr) 2002-12-28
AU3781297A (en) 1998-04-14
TR199900590T2 (xx) 1999-07-21

Similar Documents

Publication Publication Date Title
US6514997B2 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
OA10996A (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
EP1609790A2 (en) Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
EP0443498A1 (en) Isoindoline derivatives
US20060229280A1 (en) Endothelin antagonists
WO2003051848A2 (en) Imidazolidineacetic acid derivatives
SK288016B6 (sk) Use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1- yl)-ethyl]-2,2-diphenylacetamide or its salt as hydrochloride for the manufacture of a medicament for the treatment of Irritable Bowel Syndrome.
AU2005201160B2 (en) Endothelin antagonists
AU725122B2 (en) Endothelin antagonists
AU2984101A (en) Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
NZ514170A (en) Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
CZ92199A3 (cs) Pyrrolidinyl- a pyrrolinylethylaminové sloučeniny, způsob a meziprodukty pro jejich výrobu, farmaceutická kompozice na jejich bázi a způsob léčení chorob
AU2008201198A1 (en) Endothelin anatagonists
MXPA00010234A (es) Procedimiento para preparar el enantiomero puro de n-metil-n- [(1s)-1- fenil-2- ((3s)-3-hidroxipirrolidin- 1-il) etil]-2,2-difenilacetamida
CZ2000348A3 (cs) Deriváty pyrrolidin-3-karboxylové kyseliny a jejich použití jako antagonistů endothelinu
JPH07291965A (ja) 新規なピロリジン誘導体